Arizona Tribune - Boulevard

NYSE - LSE

CMSD	-0.34%	20.69	$
CMSC	-0.53%	20.81	$
BCC	2.64%	79.21	$
RIO	0.42%	103.27	$
RELX	-3.21%	35.51	$
BCE	-0.59%	23.67	$
RBGPF	0%	70	$
JRI	-0.58%	12.14	$
NGG	-0.06%	78.12	$
GSK	-1.96%	49.89	$
AZN	-1.27%	162.7	$
BTI	-1.12%	55.35	$
VOD	1.89%	16.9	$
RYCEF	0.7%	19.92	$
BP	0.52%	43.81	$

Featured

How haze from Indonesian fires impacts Southeast Asia

Thick smog has blanketed parts of Indonesia as the vast archipelago for weeks battles to contain fires that have burned large swathes of Borneo and Sumatra.

Tetris distances itself from controversial White House 'arcade' games

Tetris said on Friday that it did not give permission for the White House to use the game's iconic imagery for a controversial online arcade that the Trump administration released on Thursday.

Last news

UN watchdog chief visits Fukushima as Japan returns to nuclear power

The UN nuclear watchdog chief visited Japan's stricken Fukushima plant on Wednesday, the day after Tokyo approved an energy plan that marks a return to nuclear power to meet growing demand for AI.

Top South Korean judge faces disinformation deluge as Yoon impeachment looms

Bogus child pornography claims, fabricated support for communism and fake posts showing Elon Musk calling for his removal -- a deluge of disinformation is targeting a top judge in suspended South Korean President Yoon Suk Yeol's impeachment trial.

Rapper A$AP Rocky found not guilty in assault trial

Rapper A$AP Rocky was found not guilty of two counts of felony assault at the conclusion of a trial in Los Angeles on Tuesday.

Havertys Announces First Quarter 2025 Cash Dividend

ATLANTA, GA / ACCESS Newswire / February 19, 2025 / HAVERTYS (NYSE:HVT and HVT.A) announced today that its board of directors declared a cash dividend to be paid on the outstanding shares of the two classes of $1 par value common stock of the company at a rate of $0.32 per share on the common stock and $0.30 per share on the Class A common stock. The dividend is payable on March 21, 2025, to stockholders of record at the close of business on March 6, 2025. Havertys has paid a cash dividend in each year since 1935.

Bausch Health Announces Fourth Quarter and Full-Year 2024 Results

Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidanceFourth Quarter Consolidated Revenues of $2.56 billion, up 6% on a Reported basis and up 9% on an Organic (non-GAAP)1 basis over the prior year periodFull-Year Consolidated Revenues of $9.63 billion, up 10% on a Reported basis and 8% on an Organic (non-GAAP)1 basis, with growth in all segmentsGAAP Net Income Attributable to Bausch Health Companies Inc. of $93 million for the quarter and GAAP Net Loss of $46 million for the yearConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $935 million for the quarter, up 8%, and $3.31 billion for the year, up 10%

Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes

LONDON, UK / ACCESS Newswire / February 19, 2025 / NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq

NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology, and PowerUp Acquisition Corp. (Nasdaq:PWUP), a Nasdaq Global Market® listed special purpose acquisition company, ("PowerUp"), today announced the completion of their previously announced business combination (the "Business Combination"). The Business Combination was approved by PowerUp Acquisition Corp. stockholders on January 31, 2025, and it closed on February 17, 2025. Beginning on February 20, 2025, Aspire Biopharma shares of common stock and warrants will begin to trade on the Nasdaq Global Market and Nasdaq Capital Market (collectively, "Nasdaq"), respectively, under the ticker symbols "ASBP" and "ASBPW," respectively.

Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)

This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and microvillus inclusion disease (MVID) in the US, EU, and/or Middle East/North Africa regionsAvailability of first IIT proof-of-concept results potentially in H1 2025Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan-Drug Designation by the FDA and the European Medicines Agency (EMA) for both SBS-IF and MVID

Exxel Pharma Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here

Dolphin Expands Loyalty Program With Exclusive New Perks

New Perks Include 2 Tickets To See Any Live Concert at The Capitol Theatre in New York plus Saysh Sneaker Discount and more

CNS Pharmaceuticals Announces Reverse Stock Split

HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-50 reverse split of its common stock. Beginning on February 21, 2025, the Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis under the trading symbol "CNSP", but will trade under the following new CUSIP number: 18978H409. The reverse stock split is primarily intended to increase the Company's per share trading price and bring the Company into compliance with the Nasdaq's listing requirement regarding minimum share price.

Cleveland Clinic Announces the Rollout of Ambience Healthcare’s AI Platform

Ambient AI technology can help reduce clinician burnout and enhance patient care

CBMJ Reduces Debt 44% by Restructuring AMP News Note - Additional Reductions to Follow Over Next Six Months

ATLANTA, GA / ACCESS Newswire / February 19, 2025 / Conservative Broadcast Media & Journalism (OTC PINK:CBMJ) announced that it has reduced its overall debt by approximately 44%. This was accomplished by restructuring the $1.89M balance owed under a $2.0M note from the original purchase by AMP News, Inc., a CBMJ wholly owned subsidiary, of the independent broadcast media, news and entertainment business assets owned by American Media Periscope LLC.

Interactive Strength Inc. (Nasdaq:TRNR) Increases 2025 Expectations to More Than $50M in Pro Forma Revenues

New Investor Presentation on Growth Strategy and Expected Sportstech Acquisition

CBDL Launches New Mushroom Supplement Drink & Smoothie Bar

The functional mushroom industry is exploding, set to surpass $69 billion by 2028, and CBDL is seizing the moment-unlocking a massive revenue opportunity with its latest game-changing expansion.

NanoViricides, Inc. Has Filed its Quarterly Report

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu

Kiffik Announces Global Partnership With Duracell(R) Batteries To Power New, Innovative Health Monitoring Technology

Duracell® batteries will be integrated into KIFFIK Biomonitoring Devices, such as health monitors, that detect various biomarkers in the body.

Compassion Center Honors Pioneering Cannabinologist Dr. David Bearman for Decades of Transformative Work in Integrative Health and Medical Cannabis, Announces Leadership Promotion Around a National Expansion

Compassion Center proudly honors Dr. David Bearman for his pioneering work in medical cannabis, integrative healthcare, and patient advocacy. As Dr. Bearman retires, his legacy lives on through initiatives like CBCCERN, TeachOneServe10.org, and IntegrativeECS, reshaping care for millions. Amie Lindsay steps into a new leadership role, driving national expansion while preserving Compassion Center's mission: providing compassionate, evidence-based care and advancing integrative medicine across the U.S.

Compassion Center Calls for Media Accountability Amid Ongoing DEA Cannabis Rescheduling Hearings

Compassion Center urges media outlets to report accurately on the DEA's active cannabis rescheduling hearings, emphasizing the importance of factual coverage during this pivotal regulatory process. Suggesting that the hearing is cancelled is a lie. Misinformation like this risks undermining patient access, public trust, and informed policymaking as the DEA evaluates moving cannabis to a Schedule III substance under the Controlled Substances Act (CSA). Compassion Center remains committed to providing expert insights and advocating for patie

Compassion Center Named a Community Partner for Psychedelic Science 2025, Ushering in a New Generation of Traditional Psychedelic-Assisted Transmutations and Clinical Research Pathways Leading Towards Total Human Wholeness

Compassion Center is proud to partner with Psychedelic Science 2025 (PS2025), the premier global conference on psychedelic research and innovation hosted by MAPS. As an exhibitor, Compassion Center will highlight pioneering psychedelic-assisted programs, clinical research pathways, and strategic partnerships that advance mental health and integrative medicine. Visitors can explore breakthroughs in PTSD, addiction, and neurodegenerative disease treatments while engaging with leaders driving equitable access to transformative therapies.

BioNxt Solutions Unveils Accelerated 90-Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti-Aging Expansion

VANCOUVER, BC / ACCESS Newswire / February 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report on several major milestones for the next 90 days, including the registration of national-level patents, the completion of a human bioequivalence study for its lead Multiple Sclerosis (MS) treatment, and the development of its longevity and anti-aging product.

Hospitalised pope has double pneumonia: Vatican

Pope Francis, who was admitted to hospital last week, has developed pneumonia in both of his lungs, the Vatican announced on Tuesday, adding that the 88-year-old was in "good spirits".

Argentine Olympic sailor's ex-trainer arrested for alleged abuse

The former trainer of an Argentine Olympic sailor has been arrested in Buenos Aires over claims by the athlete and others that he sexually abused them in their teens, legal sources said Tuesday.

Video shows Toronto plane's hard landing before flipping

The passenger plane that crashed in Toronto appeared to hit the runway hard before bursting into flames and flipping upside down, new video showed Tuesday.

'Let out your inner granny': Knits at the flicks craze grips Vienna

Armed with yarn, needles and hooks, dexterous moviegoers flock to a cinema in Vienna every month to combine their favourite hobbies: knits and flicks.

Delta plane flips upside down in Toronto crash, at least 18 injured

A Delta Air Lines jet with 80 people onboard crash-landed Monday at Toronto's main airport, officials said, flipping upside down and leaving at least 18 people injured but causing no deaths.

Argentina's Milei denies role in 'cryptogate' as prosecutors launch probe

Argentine President Javier Milei on Monday denied promoting a cryptocurrency that crashed, losing investors billions of dollars and prompting a flood of complaints, as prosecutors reportedly prepare an investigation into the scandal.

Delta plane flips upside down in Toronto crash, at least 17 injured

A Delta Air Lines jet with 80 people onboard crash landed Monday at the Toronto airport, officials said, flipping upside down and leaving at least 17 people injured but causing no fatalities.

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will present at the 6th Glioblastoma Drug Development Summit being held February 18-20, 2025 in Boston, MA.

Medicure Announces Expansion of Its Pharmacy Business Through Signing of a Purchase Agreement for the Acquisition of Gateway Medical Pharmacy

WINNIPEG, MB / ACCESS Newswire / February 18, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that through its wholly-owned U.S. subsidiary, Medicure Pharma Inc., it has signed a definitive agreement on February 14, 2025 to acquire 100% of Gateway Medical Pharmacy Inc. ("Gateway") from an arms-length third-party (the "Proposed Transaction"). Gateway generated unaudited revenue of approximately $3.1 million and net income of $271,000 for the 12-month period ended December 31, 2024.

Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting

HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the acceptance of seventeen abstracts for presentation at the AACR Annual Meeting, in Chicago, IL (April 25-30, 2025). These presentations will highlight Champions' cutting-edge research, featuring innovative in vivo and organoid platforms for oncology and immuno-oncology drug testing, as well as AI-driven models that utilize multi-omics datasets to predict patient outcomes.

Arizona Tribune - Boulevard (English)